Anavex life sciences to report new long-term oral blarcamesine phase iib/iii alzheimer's disease data at j.p. morgan 2025 healthcare conference

Topline data from attention-ad open-label-extension (ole) 96/144-week trial j.p. morgan 2025 healthcare conference, taking place january 13–16, 2025, in san francisco, ca new york, dec. 09, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today announced its upcoming presentation of topline long-term data from the phase iib/iii attention-ad open-label-extension (ole) trial at the j.p.
AVXL Ratings Summary
AVXL Quant Ranking